AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBIX
  4. [Form 4] Neurocrine Biosciences Inc Insider Trading Activity

[Form 4] Neurocrine Biosciences Inc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Pearl Diver Credit Company Inc. (NYSE: PDCC) filed a Form 8-K to disclose a single data point under Item 8.01 鈥� Other Events. Management has calculated the company鈥檚 unaudited net asset value (NAV) per common share at $18.19 as of June 30, 2025. No additional financial statements, earnings details, or transaction announcements were included. The filing is therefore informational, providing shareholders with an updated valuation reference ahead of future periodic reports.

Pearl Diver Credit Company Inc. (NYSE: PDCC) ha presentato un modulo 8-K per comunicare un singolo dato sotto la voce Articolo 8.01 鈥� Altri Eventi. La direzione ha calcolato il valore patrimoniale netto non revisionato (NAV) per azione ordinaria pari a 18,19$ al 30 giugno 2025. Non sono stati inclusi ulteriori bilanci, dettagli sugli utili o annunci di transazioni. La comunicazione ha quindi carattere informativo, offrendo agli azionisti un riferimento aggiornato di valutazione in vista dei futuri rapporti periodici.

Pearl Diver Credit Company Inc. (NYSE: PDCC) present贸 un Formulario 8-K para divulgar un 煤nico dato bajo el Punto 8.01 鈥� Otros Eventos. La direcci贸n ha calculado el valor neto de activos no auditado (NAV) por acci贸n com煤n en $18.19 al 30 de junio de 2025. No se incluyeron estados financieros adicionales, detalles de ganancias ni anuncios de transacciones. Por lo tanto, la presentaci贸n es informativa, proporcionando a los accionistas una referencia de valoraci贸n actualizada antes de los futuros informes peri贸dicos.

Pearl Diver Credit Company Inc. (NYSE: PDCC)電� 頃 8.01 鈥� 旮绊儉 靷贝鞐� 霐半澕 雼澕 雿办澊韯� 韽澑韸鸽ゼ 瓿店皽頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 瓴届榿歆勳潃 2025雲� 6鞗� 30鞚� 旮办 氙戈皭靷� 靾滌瀽靷瓣皜旃�(NAV) 氤错喌欤茧嫻 18.19雼煬毳� 靷办稖頄堨姷雼堧嫟. 於旉皜 鞛鞝滍憸, 靾橃澋 靹鸽秬靷暛 霕愲姅 瓯半灅 瓿奠電� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 霐半澕靹� 鞚� 鞝滌稖鞚� 鞝曤炒 鞝滉车 氇╈爜鞚措┌, 欤检＜霌れ棎瓴� 頄ロ泟 鞝曣赴 氤搓碃靹� 鞝勳棎 鞐呺嵃鞚错姼霅� 韽夑皜 旮办鞚� 鞝滉车頃╇媹雼�.

Pearl Diver Credit Company Inc. (NYSE : PDCC) a d茅pos茅 un formulaire 8-K pour divulguer un seul point de donn茅es sous l鈥橝rticle 8.01 鈥� Autres 茅v茅nements. La direction a calcul茅 la valeur d鈥檃ctif nette non audit茅e (VAN) par action ordinaire 脿 18,19 $ au 30 juin 2025. Aucun autre 茅tat financier, d茅tail sur les b茅n茅fices ou annonce de transaction n鈥檃 茅t茅 inclus. Ce d茅p么t est donc 脿 but informatif, fournissant aux actionnaires une r茅f茅rence de valorisation mise 脿 jour avant les prochains rapports p茅riodiques.

Pearl Diver Credit Company Inc. (NYSE: PDCC) hat ein Formular 8-K eingereicht, um einen einzelnen Datenpunkt unter Punkt 8.01 鈥� Sonstige Ereignisse offenzulegen. Das Management hat den unauditierten Nettoinventarwert (NAV) je Stammaktie mit 18,19 USD zum 30. Juni 2025 berechnet. Es wurden keine zus盲tzlichen Finanzberichte, Gewinnangaben oder Transaktionsank眉ndigungen beigef眉gt. Die Einreichung dient somit rein informativen Zwecken und bietet den Aktion盲ren eine aktualisierte Bewertungsreferenz vor zuk眉nftigen periodischen Berichten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 8-K only updates NAV to $18.19; no other material events disclosed.

The sole disclosure鈥攎anagement鈥檚 unaudited NAV per share of $18.19鈥攐ffers investors a refreshed measure of book value but lacks comparative context to judge performance momentum. Without prior-period NAV, portfolio composition, or earnings metrics, the impact on valuation models is limited. Such NAV updates are routine for credit funds and business-development companies; thus, market reaction should be muted unless subsequent filings reveal material shifts.

Pearl Diver Credit Company Inc. (NYSE: PDCC) ha presentato un modulo 8-K per comunicare un singolo dato sotto la voce Articolo 8.01 鈥� Altri Eventi. La direzione ha calcolato il valore patrimoniale netto non revisionato (NAV) per azione ordinaria pari a 18,19$ al 30 giugno 2025. Non sono stati inclusi ulteriori bilanci, dettagli sugli utili o annunci di transazioni. La comunicazione ha quindi carattere informativo, offrendo agli azionisti un riferimento aggiornato di valutazione in vista dei futuri rapporti periodici.

Pearl Diver Credit Company Inc. (NYSE: PDCC) present贸 un Formulario 8-K para divulgar un 煤nico dato bajo el Punto 8.01 鈥� Otros Eventos. La direcci贸n ha calculado el valor neto de activos no auditado (NAV) por acci贸n com煤n en $18.19 al 30 de junio de 2025. No se incluyeron estados financieros adicionales, detalles de ganancias ni anuncios de transacciones. Por lo tanto, la presentaci贸n es informativa, proporcionando a los accionistas una referencia de valoraci贸n actualizada antes de los futuros informes peri贸dicos.

Pearl Diver Credit Company Inc. (NYSE: PDCC)電� 頃 8.01 鈥� 旮绊儉 靷贝鞐� 霐半澕 雼澕 雿办澊韯� 韽澑韸鸽ゼ 瓿店皽頃橁赴 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 瓴届榿歆勳潃 2025雲� 6鞗� 30鞚� 旮办 氙戈皭靷� 靾滌瀽靷瓣皜旃�(NAV) 氤错喌欤茧嫻 18.19雼煬毳� 靷办稖頄堨姷雼堧嫟. 於旉皜 鞛鞝滍憸, 靾橃澋 靹鸽秬靷暛 霕愲姅 瓯半灅 瓿奠電� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 霐半澕靹� 鞚� 鞝滌稖鞚� 鞝曤炒 鞝滉车 氇╈爜鞚措┌, 欤检＜霌れ棎瓴� 頄ロ泟 鞝曣赴 氤搓碃靹� 鞝勳棎 鞐呺嵃鞚错姼霅� 韽夑皜 旮办鞚� 鞝滉车頃╇媹雼�.

Pearl Diver Credit Company Inc. (NYSE : PDCC) a d茅pos茅 un formulaire 8-K pour divulguer un seul point de donn茅es sous l鈥橝rticle 8.01 鈥� Autres 茅v茅nements. La direction a calcul茅 la valeur d鈥檃ctif nette non audit茅e (VAN) par action ordinaire 脿 18,19 $ au 30 juin 2025. Aucun autre 茅tat financier, d茅tail sur les b茅n茅fices ou annonce de transaction n鈥檃 茅t茅 inclus. Ce d茅p么t est donc 脿 but informatif, fournissant aux actionnaires une r茅f茅rence de valorisation mise 脿 jour avant les prochains rapports p茅riodiques.

Pearl Diver Credit Company Inc. (NYSE: PDCC) hat ein Formular 8-K eingereicht, um einen einzelnen Datenpunkt unter Punkt 8.01 鈥� Sonstige Ereignisse offenzulegen. Das Management hat den unauditierten Nettoinventarwert (NAV) je Stammaktie mit 18,19 USD zum 30. Juni 2025 berechnet. Es wurden keine zus盲tzlichen Finanzberichte, Gewinnangaben oder Transaktionsank眉ndigungen beigef眉gt. Die Einreichung dient somit rein informativen Zwecken und bietet den Aktion盲ren eine aktualisierte Bewertungsreferenz vor zuk眉nftigen periodischen Berichten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Onyia Jude
(Last) (First) (Middle)
6027 EDGEWOOD BEND CT.
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/09/2025 M 59,819 A $84.74 78,108 D
Common Stock 07/09/2025 S(1) 59,819 D $130.455(2) 18,289 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option $84.74 07/09/2025 M 59,819 (3) 11/29/2031 Common Stock 59,819 $0 35,268 D
Explanation of Responses:
1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $131.45. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Pearl Diver Credit Company (PDCC) report in its July 11 2025 Form 8-K?

Management disclosed an unaudited NAV per common share of $18.19 as of June 30 2025.

Does the 8-K include earnings or revenue figures for PDCC?

No. The filing only provides the NAV per share; it contains no income statement or cash-flow data.

Is the $18.19 NAV figure audited?

The company specifies the figure as unaudited; it has not been reviewed by external auditors.

Were any dividends or share-repurchase plans announced for PDCC or PDPA preferred stock?

No dividends, repurchase programs, or other capital actions were disclosed in this 8-K.

Why might PDCC issue an 8-K for a NAV update?

Registered investment companies and BDC-like credit funds often provide interim NAV updates to keep investors informed between quarterly reports.
Stock NBIX logo
Neurocrine Biosciences Inc

NASDAQ:NBIX

NBIX Rankings

#1157 Ranked by Market Cap
N/A Ranked by Dividends

NBIX Latest News

Jul 30, 2025
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Jul 15, 2025
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
Jul 15, 2025
Neurocrine Biosciences Presents New Analysis of CAHtalog庐 Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Jul 14, 2025
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst鈩� Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Jul 14, 2025
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY庐 (crinecerfont) in Adult Patients, at ENDO 2025

NBIX Latest SEC Filings

Jul 30, 2025
[10-Q] Neurocrine Biosciences Inc Quarterly Earnings Report
Jul 30, 2025
[8-K] Neurocrine Biosciences Inc Reports Material Event
Jul 11, 2025
[Form 4] Neurocrine Biosciences Inc Insider Trading Activity
Jul 10, 2025
[144] Neurocrine Biosciences Inc SEC Filing
Jul 7, 2025
[Form 4] Neurocrine Biosciences Inc Insider Trading Activity

NBIX Stock Data

13.28B
96.88M
1.02%
97.9%
3.24%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO